Compare VERA & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERA | DKL |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.4B |
| IPO Year | 2021 | N/A |
| Metric | VERA | DKL |
|---|---|---|
| Price | $46.84 | $47.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $76.60 | $45.50 |
| AVG Volume (30 Days) | ★ 1.5M | 50.6K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 9.34% |
| EPS Growth | N/A | ★ 9.17 |
| EPS | N/A | ★ 3.09 |
| Revenue | N/A | ★ $967,420,000.00 |
| Revenue This Year | N/A | $11.84 |
| Revenue Next Year | N/A | $10.55 |
| P/E Ratio | ★ N/A | $15.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.53 | $34.59 |
| 52 Week High | $56.05 | $48.00 |
| Indicator | VERA | DKL |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 64.62 |
| Support Level | $47.22 | $44.60 |
| Resistance Level | $56.05 | $45.50 |
| Average True Range (ATR) | 2.35 | 1.04 |
| MACD | -1.00 | 0.24 |
| Stochastic Oscillator | 9.63 | 95.58 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.